Contineum Therapeutics Submits Phase 2 Trial for PIPE-791

Contineum Therapeutics, Inc. Class A ( (CTNM) ) has shared an announcement.

On December 8, 2025, Contineum Therapeutics, Inc. Class A announced the submission of its global Phase 2 clinical trial details for PIPE-791, aimed at treating idiopathic pulmonary fibrosis (IPF), to the ClinicalTrials.gov Protocol Registration and Results System. The trial, which is expected to enroll approximately 324 subjects globally, will evaluate the safety, tolerability, and efficacy of PIPE-791 over a 26-week period. The company plans to complete the trial by June 2028, with the trial design informed by previous regulatory engagement and Phase 1 clinical trials. This initiative highlights the company’s commitment to advancing treatment options for IPF, although it faces substantial risks and uncertainties related to clinical drug development, regulatory approvals, and market competition.

The most recent analyst rating on (CTNM) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.

Spark’s Take on CTNM Stock

According to Spark, TipRanks’ AI Analyst, CTNM is a Underperform.

Contineum Therapeutics, Inc. receives a low stock score due to significant financial struggles, including a lack of revenue and negative profitability. The technical analysis reveals a bearish trend, and the valuation is weak with a negative P/E ratio. While there are some positives in terms of debt reduction and cash reserves, these are overshadowed by the company’s operational challenges and weak market momentum.

To see Spark’s full report on CTNM stock, click here.

More about Contineum Therapeutics, Inc. Class A

Average Trading Volume: 159,849

Technical Sentiment Signal: Strong Buy

Current Market Cap: $368.9M

Find detailed analytics on CTNM stock on TipRanks’ Stock Analysis page.